Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant and malignant cells. Unlike traditional tests that detect cell tumor lumps in the breast when cancer has advanced into a mature state, this test can detect cancer risk years before tumor build up. The test is a non-invasive, 5 minute procedure that is fully automated and can be used in busy primary care settings, yet still provides doctors with advanced diagnostic results. Novel diagnostics that can identify the presence of malignant tissue in the breast with increased sensitivity, at earlier stages, is essential for the improved and successful treatment of breast cancer, the second leading cause of cancer death in women.
Categories: cancer, COMPANIES, Diagnostics, Technology Report
